Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Arbaclofen for Social Function in Children and Adolescents With Autism Spectrum Disorders
2018-000942-21Phase 2Unknown
- Sponsor
- Celso Arango
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Arbaclofen with Placebo (2 arms). Primary endpoint: Vineland-3 Socialization Domain. Status: unknown.
02
Drugs
arbaclofen
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2018-000942-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000942-21.